Cargando…
Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer
BACKGROUND: To determine the 5-year outcome after high-dose-rate brachytherapy (HDR-BT) as a monotherapy. METHODS: Between 10/2003 and 06/2006, 36 patients with low (28) and intermediate (8) risk prostate cancer were treated by HDR-BT monotherapy. All patients received one implant and 4 fractions of...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046044/ https://www.ncbi.nlm.nih.gov/pubmed/24885327 http://dx.doi.org/10.1186/1748-717X-9-122 |
_version_ | 1782319441495719936 |
---|---|
author | Ghadjar, Pirus Oesch, Sebastian L Rentsch, Cyrill A Isaak, Bernhard Cihoric, Nikola Manser, Peter Thalmann, George N Aebersold, Daniel M |
author_facet | Ghadjar, Pirus Oesch, Sebastian L Rentsch, Cyrill A Isaak, Bernhard Cihoric, Nikola Manser, Peter Thalmann, George N Aebersold, Daniel M |
author_sort | Ghadjar, Pirus |
collection | PubMed |
description | BACKGROUND: To determine the 5-year outcome after high-dose-rate brachytherapy (HDR-BT) as a monotherapy. METHODS: Between 10/2003 and 06/2006, 36 patients with low (28) and intermediate (8) risk prostate cancer were treated by HDR-BT monotherapy. All patients received one implant and 4 fractions of 9.5 Gy within 48 hours for a total prescribed dose (PD) of 38 Gy. Five patients received concomitant androgen deprivation therapy (ADT). Toxicity was scored according to the common terminology criteria for adverse events from the National Cancer Institute (CTCAE) version 3.0. Biochemical recurrence was defined according to the Phoenix criteria and analyzed using the Kaplan Meier method. Predictors for late grade 3 GU toxicity were analyzed using univariate and multivariate Cox regression analyses. RESULTS: The median follow-up was 6.9 years (range, 1.5-8.0 years). Late grade 2 and 3 genitourinary (GU) toxicity was observed in 10 (28%) and 7 (19%) patients, respectively. The actuarial proportion of patients with late grade 3 GU toxicity at 5 years was 17.7%. Late grade 2 and 3 gastrointestinal (GI) toxicities were not observed. The crude erectile function preservation rate in patients without ADT was 75%. The 5 year biochemical recurrence-free survival (bRFS) rate was 97%. Late grade 3 GU toxicity was associated with the urethral volume (p = 0.001) and the urethral V(120) (urethral volume receiving ≥120% of the PD; p = 0.0005) after multivariate Cox regression. CONCLUSIONS: After HDR-BT monotherapy late grade 3 GU was observed relatively frequently and was associated with the urethral V(120). GI toxicity was negligible, the erectile function preservation rate and the bRFS rate was excellent. |
format | Online Article Text |
id | pubmed-4046044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40460442014-06-06 Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer Ghadjar, Pirus Oesch, Sebastian L Rentsch, Cyrill A Isaak, Bernhard Cihoric, Nikola Manser, Peter Thalmann, George N Aebersold, Daniel M Radiat Oncol Research BACKGROUND: To determine the 5-year outcome after high-dose-rate brachytherapy (HDR-BT) as a monotherapy. METHODS: Between 10/2003 and 06/2006, 36 patients with low (28) and intermediate (8) risk prostate cancer were treated by HDR-BT monotherapy. All patients received one implant and 4 fractions of 9.5 Gy within 48 hours for a total prescribed dose (PD) of 38 Gy. Five patients received concomitant androgen deprivation therapy (ADT). Toxicity was scored according to the common terminology criteria for adverse events from the National Cancer Institute (CTCAE) version 3.0. Biochemical recurrence was defined according to the Phoenix criteria and analyzed using the Kaplan Meier method. Predictors for late grade 3 GU toxicity were analyzed using univariate and multivariate Cox regression analyses. RESULTS: The median follow-up was 6.9 years (range, 1.5-8.0 years). Late grade 2 and 3 genitourinary (GU) toxicity was observed in 10 (28%) and 7 (19%) patients, respectively. The actuarial proportion of patients with late grade 3 GU toxicity at 5 years was 17.7%. Late grade 2 and 3 gastrointestinal (GI) toxicities were not observed. The crude erectile function preservation rate in patients without ADT was 75%. The 5 year biochemical recurrence-free survival (bRFS) rate was 97%. Late grade 3 GU toxicity was associated with the urethral volume (p = 0.001) and the urethral V(120) (urethral volume receiving ≥120% of the PD; p = 0.0005) after multivariate Cox regression. CONCLUSIONS: After HDR-BT monotherapy late grade 3 GU was observed relatively frequently and was associated with the urethral V(120). GI toxicity was negligible, the erectile function preservation rate and the bRFS rate was excellent. BioMed Central 2014-05-28 /pmc/articles/PMC4046044/ /pubmed/24885327 http://dx.doi.org/10.1186/1748-717X-9-122 Text en Copyright © 2014 Ghadjar et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Ghadjar, Pirus Oesch, Sebastian L Rentsch, Cyrill A Isaak, Bernhard Cihoric, Nikola Manser, Peter Thalmann, George N Aebersold, Daniel M Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer |
title | Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer |
title_full | Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer |
title_fullStr | Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer |
title_full_unstemmed | Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer |
title_short | Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer |
title_sort | late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046044/ https://www.ncbi.nlm.nih.gov/pubmed/24885327 http://dx.doi.org/10.1186/1748-717X-9-122 |
work_keys_str_mv | AT ghadjarpirus latetoxicityandfiveyearoutcomesafterhighdoseratebrachytherapyasamonotherapyforlocalizedprostatecancer AT oeschsebastianl latetoxicityandfiveyearoutcomesafterhighdoseratebrachytherapyasamonotherapyforlocalizedprostatecancer AT rentschcyrilla latetoxicityandfiveyearoutcomesafterhighdoseratebrachytherapyasamonotherapyforlocalizedprostatecancer AT isaakbernhard latetoxicityandfiveyearoutcomesafterhighdoseratebrachytherapyasamonotherapyforlocalizedprostatecancer AT cihoricnikola latetoxicityandfiveyearoutcomesafterhighdoseratebrachytherapyasamonotherapyforlocalizedprostatecancer AT manserpeter latetoxicityandfiveyearoutcomesafterhighdoseratebrachytherapyasamonotherapyforlocalizedprostatecancer AT thalmanngeorgen latetoxicityandfiveyearoutcomesafterhighdoseratebrachytherapyasamonotherapyforlocalizedprostatecancer AT aebersolddanielm latetoxicityandfiveyearoutcomesafterhighdoseratebrachytherapyasamonotherapyforlocalizedprostatecancer |